Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Gene editing is now reaching the mainstream, ushering in a new era of genetic manipulation. Traditionally, inserting or deleting entire genes, regulating their expression, and altering specific ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

The UK is poised to lead the next great leap in agriculture, with gene-editing technology offering a lifeline to a ...

MGX’s gene editing uses metagenomics and AI to build ... So far, MGX’s tools include nucleases, base editors, and CRISPR transposases that could help with hemophilia A. It’s also possible ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics laboratory in Bengaluru.

Beyond Casgevy, CRISPR Therapeutics continues ... In the realm of in vivo gene editing, CRISPR Therapeutics is progressing with programs such as CTX310 and CTX320, targeting cardiovascular diseases.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Bengaluru (Karnataka) [India], January 16: Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics laboratory in Bengaluru.

CRISPR can be used to make other types of edits too, such as increasing or decreasing the effects of a gene temporarily. Regardless of the type of editing, the process generally remains limited to ...